Newron Pharmaceuticals - Pivotal progress on schizophrenia therapy
Newron, a Switzerland-quoted Italian company, is developing evenamide (30mg twice per day) to meet the major unmet need for new therapies to help...
335 Views
Newron Pharmaceuticals - Evenamide validation underway
Newron is developing evenamide (30mg twice per day) as an add-on to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase...
1.2k Views
Newron Pharmaceuticals - Evenamide Phase III at 30mg twice daily dose
Newron is developing evenamide as an add-on to existing anti-psychotic therapies to treat poorly managed and refractory schizophrenia. A...
995 Views
Newron Pharmaceuticals - Long-term generic challenge to Xadago
The FDA has notified Newron that an application for a generic safinamide (Xadago) has been filed. Xadago has new chemical entity (NCE) exclusivity...
408 Views
Newron Pharmaceuticals - Evenamide trial progressing well
Newron has reported excellent, fast recruitment for the Phase II study of its novel schizophrenia drug, Evenamide, due to report in Q121. Newron...
97 Views